Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
The objective of this study was to assess the safety and efficacy of doxazosin in a substantial cohort of hypertensive patients drawn from general practice. A total of 4027 patients entered the study, 1472 of whom (36.6%) were untreated hypertensive patients. Patients were not advised to change diet, smoking habit, or life-style during the study. Twenty-one percent were cigarette smokers, and concurrent diabetes was present in 2.3%. Baseline blood cholesterol exceeded 200 mg/dl (5.2 mmol/L) in 90% and 250 mg/dl (6.5 mmol/L) in 56% of patients. The mean decrease in blood pressure produced by doxazosin was 22/15 mm Hg after 10 weeks of therapy; there was a mean decrease in heart rate of 1 beat/min. The mean maintenance dose for all patients was 3.1 mg/day. Side effects considered related or possibly related to treatment were reported in 705 patients. Treatment was discontinued in 233 patients (5.8%) because of adverse events related or possibly related to treatment with doxazosin. Doxazosin produced a significant (p less than 0.001) decrease in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels and a significant increase in high-density lipoprotein cholesterol and the ratio of high-density lipoprotein:total cholesterol. The potential reduction in 10-year coronary heart disease risk (according to the Framingham equation) was calculated to be 20.4%.
Langdon
C G
CG
Symons Medical Centre, Berkshire, England.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D003327:Coronary Disease / Q000453:epidemiology; D017292:Doxazosin; D004739:England / Q000453:epidemiology; D005194:Family Practice; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology
D000959:Antihypertensive Agents; D002784:Cholesterol; D017292:Doxazosin; D011224:Prazosin